Hormone Resistant Prostate Cancer 
This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
This page shows you the latest news and research items in this category.
Hormone therapy for endometrial cancer targets connective tissue, not tumor cells
In this study, we found that all of the progesterone anti-tumor effects are in fact mediated through the stroma, even though it makes up a minor fraction of the tumor. I believe these exciting findings are going to surprise the clinical community and change the way people look at patterns of hormone-receptor expression in endometrial tumors."
The results of the three-year study, done using a specially developed laboratory model created by Memarzadeh's team that closely mimics human endometrial cancer, appear in the early online edition of Cancer Research, a peer-reviewed journal of the American Association for Cance...
Source: UCLA Newsroom: Health Sciences - June 13, 2013 Category: Universities & Medical Training Source Type: news
Study Finds Bird Virus Promising For Prostate Cancer Treatment
A study at the Virginia-Maryland Regional College of Veterinary Medicine has identified a chicken-killing virus as a promising treatment for prostate cancer in humans. Researchers have discovered that a genetically engineered Newcastle disease virus, which harms chickens but not humans, kills prostate cancer cells of all kinds, including hormone-resistant cancer cells. The work of Dr. Elankumaran Subbiah, associate professor of virology in the Department of Biomedical Sciences and Pathobiology, along with Dr... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2013 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
Researchers find avian virus may be harmful to cancer cells
(Virginia Tech) Researchers have discovered that a genetically engineered Newcastle disease virus, which harms chickens but not humans, kills prostate cancer cells of all kinds, including hormone-resistant cancer cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 8, 2013 Category: Global & Universal Source Type: news
Re: 11C-Choline PET/CT in Patients with Hormone-Resistant Prostate Cancer Showing Biochemical Relapse After Radical Prostatectomy
F. Ceci, P. Castellucci, M. Mamede, R. Schiavina, D. Rubello, C. Fuccio, V. Ambrosini, S. Boschi, G. Martorana and S. Fanti Nuclear Medicine Unit, Department of Haematology, Oncology and Laboratory Medicine, Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, University of Bologna, Bologna, Italy (Source: The Journal of Urology)
Source: The Journal of Urology - March 7, 2013 Category: Urology & Nephrology Authors: Samir S. Taneja Tags: Urological Oncology: Prostate Cancer Source Type: research
Promising Viral Treatment For Prostate Cancer Without Unpleasant Side Effects
A recombinant Newcastle disease virus kills all kinds of prostate cancer cells, including hormone resistant cells, but leaves normal cells unscathed, according to a paper published online ahead of print in the Journal of Virology. A treatment for prostate cancer based on this virus would avoid the adverse side effects typically associated with hormonal treatment for prostate cancer, as well as those associated with cancer chemotherapies generally, says corresponding author Subbiah Elankumaran of Virginia Polytechnic Institute, Blacksburg... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 27, 2013 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
Virus shows promise as prostate cancer treatment
(American Society for Microbiology) A recombinant Newcastle disease virus kills all kinds of prostate cancer cells, including hormone resistant cells, but leaves normal cells unscathed, according to a paper published online ahead of print in the Journal of Virology. A treatment for prostate cancer based on this virus would avoid the adverse side effects typically associated with hormonal treatment for prostate cancer, as well as those associated with cancer chemotherapies generally. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 25, 2013 Category: Global & Universal Source Type: news
Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone-Resistant Metastatic Prostate cancer.
CONCLUSION: Addition of anti-angiogenic agents, such as thalidomide, can improve therapeutic outcome in this group of patients.
PMID: 23235972 [PubMed - in process] (Source: Urology Journal)
Source: Urology Journal - December 20, 2012 Category: Urology & Nephrology Authors: Rezvani H, Haghighi S, Ghadyani M, Attarian H Tags: Urol J Source Type: research
Denosumab osteonecrosis of the mandible: A new entity?A case report
Abstract: In the treatment of osteoporosis, M. Kahler and bone metastases from prostate and breast cancer bisphosphonates play a major role. Not all patients respond well to bisphosphonate treatment. Since a few years adverse effects of these drugs have been reported. A new drug, denosumab, a fully human monoclonal antibody to RANKL, has recently been developed. This case reports a 74-year-old male patient with a medical history of diabetes mellitus, angina pectoris, coronary bypasses, hypertension, and prostate cancer with multiple metastases to lymph nodes, bone and lungs. The prostate cancer was treated according to the...
Source: Journal of Cranio-Maxillofacial Surgery - December 20, 2012 Category: ENT & OMF Authors: Sarina E.C. Pichardo, Sophie C.C. Kuypers, J.P. Richard van Merkesteyn Source Type: research
11C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy
Conclusion In our patient population, 11C-choline PET/CT was able to detect relapsed disease in a large proportion of HT-resistant PC patients during HT. These data,
obtained in a large series, suggest that HT withdrawal before performing a 11C-choline PET/CT scan may not be necessary for the detection of recurrent disease if PSA levels are increasing and PSA kinetics
are rapid.
Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00259-012-2272-zAuthors
Francesco Ceci, Nuclear Medicine Unit, Department of Haematology Oncology and Laboratory Medicine, Azienda Ospedaliero-Univer...
Source: European Journal of Nuclear Medicine and Molecular Imaging - November 14, 2012 Category: Radiology Tags: European Journal of Nuclear Medicine and Molecular Imaging Source Type: research
Moving toward personalized medicine in castration-resistant prostate cancer.
Abstract
Recent advances in research technologies have allowed improved molecular characterization of castration-resistant prostate cancer (CRPC). These efforts hold promise for development of therapies that target alterations unique to an individual patient's prostate cancer. Targets include androgens and the androgen receptor pathway, pathways associated with hormone-resistant disease, and the immune system. In aggregate, this will allow physicians to choose treatments based on a particular tumor profile. As these approaches are developed, CRPC treatment is becoming an example of truly personalized medicine.
...
Source: The Urologic Clinics of North America - November 1, 2012 Category: Urology & Nephrology Authors: Van Allen EM, Pomerantz M Tags: Urol Clin North Am Source Type: research
Increased expression of activated endothelial nitric oxide synthase contributes to antiandrogen resistance in prostate cancer cells by suppressing androgen receptor transactivation
Highlights: ► We developed an in vitro model LNCaP-BC of antiandrogen-resistant prostate cancer cells by long-term bicalutamide treatment. ► Increased expression of activated eNOS and NO production is acquired in bicalutamide-resistant LNCaP-BC cells. ► Clinical hormone-refractory prostate cancer also shows increased eNOS expression pattern. ► Increased NO production suppresses AR activity and contributes to antiandrogen-resistant and androgen-insensitive growth. ► Antiandrogen-resistance and suppressed AR transactivation in LNCaP-BC cells can be attenuated by inhibition of NOS activity.Abstract: Development of a...
Source: Cancer Letters - October 11, 2012 Category: Cancer & Oncology Authors: Shan Yu, Lin Jia, Yan Zhang, Dinglan Wu, Zhenyu Xu, Chi-Fai Ng, Kenneth K.W. To, Yu Huang, Franky L. Chan Tags: Research Articles Source Type: research
Xanthohumol impairs human prostate cancer cell growth and invasion, and diminishes the incidence and progression of advanced tumors in TRAMP mice.
In this study, we have used human hormone-resistant prostate cancer cells, DU145 and PC3, as an in vitro model to assess the efficacy of xanthohumol (XN) against cell growth, motility and invasion. We observed that treatment of prostate cancer cells with low micromolar doses of XN inhibits proliferation and modulates FAK and AKT phosphorylation leading to reduced cell migration and invasion. Oxidative stress by increased production of reactive oxygen species (ROS) was associated with these effects. TRAMP transgenic mice were used as in-vivo model of prostate adenocarcinoma. Oral gavage of XN, three times per week, beginnin...
Source: Molecular Medicine - August 29, 2012 Category: Molecular Biology Authors: Venè R, Benelli R, Minghelli S, Astigiano S, Tosetti F, Ferrari N Tags: Mol Med Source Type: research
Moving Toward Personalized Medicine in Castration-Resistant Prostate Cancer
Recent advances in research technologies have allowed improved molecular characterization of castration-resistant prostate cancer (CRPC). These efforts hold promise for development of therapies that target alterations unique to an individual patient's prostate cancer. Targets include androgens and the androgen receptor pathway, pathways associated with hormone-resistant disease, and the immune system. In aggregate, this will allow physicians to choose treatments based on a particular tumor profile. As these approaches are developed, CRPC treatment is becoming an example of truly personalized medicine. (Source: Urologic Cli...
Source: Urologic Clinics of North America - August 28, 2012 Category: Urology & Nephrology Authors: Eliezer M. Van Allen, Mark Pomerantz Source Type: research
Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer
Abstract In vitro studies have implicated neuroendocrine differentiation in the development of hormone resistant prostate cancer following
administration of androgen blockers. Studies on clinical material are equivocal. We wished to understand the significance
of neuroendocrine differentiation in our large and well-characterised cohort of clinically localised prostate cancer, treated
conservatively. Immunohistochemical expression of chromogranin-A was assessed semi-quantitatively on tissue samples of 806
patients in a tissue microarray approach. The correlation of expression with 10-year prostate cancer surv...
Source: Virchows Archiv - July 5, 2012 Category: Pathology Tags: Virchows Archiv Source Type: research
Split-course RT valuable after hormone-resistant prostate cancer relapse
A split course of high-dose radiotherapy in men with progressive, hormone-refractory prostate cancer is effective and has an acceptable toxicity profile, report Australian researchers. (Source: MedWire News - Prostate Cancer)
Source: MedWire News - Prostate Cancer - June 20, 2012 Category: Cancer & Oncology Source Type: news
Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells
In conclusion, altered IL-6/STAT3 signaling is crucial in HR transition,
aggressive behavior, and MDSC recruitment. These findings provide evidence for therapeutically targeting IL-6 signaling in
prostate cancer.
Content Type Journal ArticleCategory Original ArticlePages 1-13DOI 10.1007/s00109-012-0916-xAuthors
Chun-Te Wu, Department of Urology, Chang Gung Memorial Hospital, Keelung, TaiwanChing-Chuan Hsieh, College of Medicine, Chang Gung University, Taoyuan, TaiwanCheng-Chia Lin, Department of Urology, Chang Gung Memorial Hospital, Keelung, TaiwanWen-Cheng Chen, College of Medicine, Chang Gung University, Taoyua...
Source: Journal of Molecular Medicine - June 3, 2012 Category: Molecular Biology Tags: Journal of Molecular Medicine Source Type: research
NHS 'OK' for prostate cancer drug Zytiga
“NHS ban on pill to treat prostate cancer is lifted,” the Daily Express has said, while the Daily Mail has warned that a “prostate cancer wonder drug” was set for approval “south of border but turned down by Scotland”. The stories focus on the fact that the prostate cancer drug abiraterone may soon be available on the NHS in certain circumstances.
These stories are based on a revised decision on draft guidance published by The National Institute for Health and Clinical Excellence (NICE), which makes recommendations about which treatments should be available on the NHS in England and Wales. It recommends that ab...
Source: NHS News Feed - May 17, 2012 Category: Consumer Health News Tags: Cancer Medication Source Type: news
The altered expression of MiR‐221/‐222 and MiR‐23b/‐27b is associated with the development of human castration resistant prostate cancer
CONCLUSIONSThis finding suggests that altered miR‐221/‐222 and miR‐23b/‐27b expression may be associated with the CRPC process. Prostate © 2011 Wiley Periodicals, Inc. (Source: The Prostate)
Source: The Prostate - November 29, 2011 Category: Urology & Nephrology Authors: Tong SunMing YangShaoyong ChenSteven BalkMark PomerantzChen‐Lin HsiehMyles BrownGwo‐Shu Mary LeePhilip W. Kantoff Tags: Original Article Source Type: research
Hormonal Therapy Promotes Hormone-Resistant Phenotype by Increasing DNMT Activity and Expression in Prostate Cancer Models.
Abstract
We hypothesized that hormonal therapy favors the development of the hormone-resistant phenotype through epigenetic mechanisms. Human prostate cancer tissues and in vitro and in vivo models were used to verify this hypothesis. We demonstrated that tumor cells continuously treated with bicalutamide (BCLT) or cultured in androgen-depleted medium progressively acquire higher DNA methyltransferase (DNMT) activity and expression than cells cultured in standard condition. Increased DNMT expression and activity also paralleled the up-regulation of truncated AR isoforms, which favors the development of the hormone-...
Source: Endocrinology - October 11, 2011 Category: Endocrinology Authors: Gravina GL, Marampon F, Piccolella M, Motta M, Ventura L, Pomante R, Popov VM, Zani BM, Pestell RG, Tombolini V, Jannini EA, Festuccia C Tags: Endocrinology Source Type: research
Onset Of Metastases Delayed In Hormone-Resistant Prostate Cancer
Inhibiting a protein involved in bone metabolism can delay the onset of the bone metastases which are common in men with a particular form of prostate cancer, a researcher told the 2011 European Multidisciplinary Cancer Congress [1]. Professor Stéphane Oudard, Head of the Oncology Department at the Georges Pompidou Hospital, Paris, France, says that his team's research on the effects of the monoclonal antibody denosumab (XGEVA TM) is the first large-scale clinical trial to show such an effect... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 26, 2011 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients
(ECCO-the European CanCer Organisation) Inhibiting a protein involved in bone metabolism can delay the onset of bone metastases common in men with prostate cancer resistant to hormone treatment. The research on the effects of the monoclonal antibody denosumab is the first large-scale clinical trial to show such an effect. The use of denosumab in this group of patients can impede the onset of bone metastases by just over four months. This research will be presented on Sept. 25 at the 2011 European Multidisciplinary Cancer Congress. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 24, 2011 Category: Global & Universal Source Type: news
[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy
Conclusion In clinical practice, [11C]choline PET/CT may not replace BS because of its lower sensitivity. However, for its high specificity, [11C]choline PET/CT positive findings may accurately predict the presence of BM. Equivocal findings are more frequent in BS than
[11C]choline PET/CT.
Content Type Journal ArticleCategory Original ArticlePages 1-14DOI 10.1007/s00259-011-1920-zAuthors
Maria Picchio, Nuclear Medicine Department, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, ItalyElena Giulia Spinapolice, Center for Molecular Bioimaging, University of Milano-Bicocca, Milan, Italy...
Source: European Journal of Nuclear Medicine and Molecular Imaging - September 20, 2011 Category: Radiology Tags: European Journal of Nuclear Medicine and Molecular Imaging Source Type: research
New drug extends survival for men with advanced prostate cancer
For men with advanced hormone-resistant prostate cancer who have also failed chemotherapy, the new drug Zytiga (abiraterone acetate) along with ... (Source: USATODAY.com Health)
Source: USATODAY.com Health - May 28, 2011 Category: Consumer Health News Source Type: news
Assessment of the Effects of Zoledronic Acid Therapy on Bone
Metabolic Indicators in Hormone-Resistant Prostate Cancer Patients
with Bone Metastatasis
Conclusion. Zoledronic acid therapy decreased bone destruction and was effective in palliation of pain in patient with bone metastasis. Using bone metabolic indicators during followup of zoledronic acid therapy might be useful. (Source: Journal of Oncology)
Source: Journal of Oncology - May 5, 2011 Category: Cancer & Oncology Source Type: research
MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines.
Prostate cancers show a slow progression from a local lesion (primary tumor) to a metastatic and hormone-resistant phenotype. After an initial step of hyperplasia, in a high percentage of cases a neoplastic transformation event occurs that, less frequently, is followed by epithelial to mesenchymal transition and invasion of healthy tissues (usually bones). MicroRNA-203 (miR-203) is a tumor suppressor microRNA often silenced in different malignancies. Here, we show that miR-203 is downregulated in clinical primary prostatic tumors compared to normal prostate tissue, and in metastatic prostate cancer cell lines compared ...
Source: Cell Cycle - March 15, 2011 Category: Cytology Authors: Viticchiè G, Lena AM, Latina A, Formosa A, Gregersen LH, Lund AH, Bernardini S, Mauriello A, Miano R, Spagnoli LG, Knight RA, Candi E, Melino G Tags: Cell Cycle Source Type: research
Denosumab Better Than Current Gold Standard Of Zoledronic Acid For Preventing Bone Events In Men With Hormone-Resistant Prostate Cancer
Prostate cancer in men usually becomes resistant to initial hormone treatment within a few years of diagnosis (and is thereafter called castration-resistant prostate cancer) and tumours begin to grow again and spread to other parts of the body (metastasis), including bones. This increases the risk of bone breakages and other bone events that cause significant disability and quality of life issues... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 25, 2011 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
Urological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines
Conclusion The process provides a useful framework for improving urological cancer care through evidence synthesis, research prioritisation,
stakeholder involvement and international collaboration. Although the focus of this work is urological cancers, the methodology
can be applied to all aspects of urology and is transferable to other clinical specialties.
Content Type Journal ArticlePages 1-11DOI 10.1007/s00345-011-0660-9Authors
Sara Jane MacLennan, Academic Urology Unit, University of Aberdeen, Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD Scotland, UKSteven J. MacLennan, Academic U...
Source: World Journal of Urology - February 24, 2011 Category: Urology & Nephrology Tags: World Journal of Urology Source Type: research
Survivin Is Associated With Cell Proliferation and Has a Role in 1a,25-Dihydroxyvitamin D3 Induced Cell Growth Inhibition in Prostate Cancer
Conclusions: Findings suggest that survivin has a significant association with prostate cancer cell proliferation and an essential role in 1a,25-dihydroxyvitamin D3 induced prostate cancer cell growth inhibition. It seems that the eliminating survivin in 1a,25-dihydroxyvitamin D3 therapy for hormone refractory prostate cancer is a potential therapeutic option. (Source: The Journal of Urology)
Source: The Journal of Urology - February 20, 2011 Category: Urology & Nephrology Authors: Hidekazu Koike, Yasuyuki Morikawa, Yoshitaka Sekine, Hiroshi Matsui, Yasuhiro Shibata, Kazuhiro Suzuki Tags: Investigative Urology Source Type: research
Potent Farnesyltransferase Inhibitors with 1,4-Diazepane Scaffolds as Novel Destabilizing Microtubule Agents in Hormone-Resistant Prostate Cancer
Journal of Medicinal ChemistryDOI: 10.1021/jm101067y (Source: Journal of Medicinal Chemistry)
Source: Journal of Medicinal Chemistry - February 7, 2011 Category: Chemistry Authors: Nicolas Wlodarczyk, Delphine Le Broc-Ryckewaert, Pauline Gilleron, Amélie Lemoine, Amaury Farce, Philippe Chavatte, Joëlle Dubois, Nicole Pommery, Jean-Pierre Hénichart, Christophe Furman and Régis Millet Source Type: research
New Drug Targets Vitamin D Receptors In Hormone Resistant Prostate Cancers: Promising Results From First Clinical Trial
A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies. Results of the phase II(a) clinical trial will be presented at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin today (Thursday)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 18, 2010 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
New drug targets vitamin D receptors in hormone resistant prostate cancers
A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 18, 2010 Category: Science Source Type: news
New drug targets vitamin D receptors in hormone resistant prostate cancers
(ECCO-the European CanCer Organisation) A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies. Results of the phase II(a) clinical trial will be presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin on Thursday. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 17, 2010 Category: Cancer & Oncology Source Type: news
Harbor BioSciences Apoptone(R) for Prostate Cancer Shows a Partial Overall Response
SAN DIEGO, Sept. 14, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(r) (HE3235) for castration resistant prostate cancer (CRPC) -- also referred to as hormone resistant prostate cancer. (Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - September 14, 2010 Category: Pharmaceuticals Source Type: news
Harbor BioSciences Apoptone® For Prostate Cancer Shows A Partial Overall Response
Harbor BioSciences, Inc. (Nasdaq:HRBR) a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) - also referred to as hormone resistant prostate cancer. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - September 14, 2010 Category: Pharmaceuticals Source Type: news
[Effects of bioactive molecules of Beta vulgaris L. ssp. esculenta var. rubra on metastatic prostate cancer.]
Conclusions: According to results, it seems that moderate and permanent consumption of table beet product affects the life expectancy of patients favorably; however, due to the increasing values of EGF, medical control is necessary for patients with prostate cancer treated by chemotherapy. Orv. Hetil., 2010, 37, 1495-1503.
PMID: 20807696 [PubMed - in process] (Source: Orvosi Hetilap)
Source: Orvosi Hetilap - September 9, 2010 Category: Journals (General) Authors: Nyirády P, Sárdi E, Beko G, Szucs M, Horváth A, Székely E, Szentmihályi K, Romics I, Blázovics A Tags: Orv Hetil Source Type: research
CRT And ValiRx Sign Licensing Deal To Develop Prostate Cancer Treatment
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer. The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 16, 2010 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
Columbia University Study Reports Breakthrough In The Fight Against Prostate Cancer
Researchers at Columbia University have published the dramatic effects of a natural 33-ingredient compound against prostate cancer cell lines. The impressive results are found in the most recent publication of Integrative Cancer Therapies. Lead researcher Dr. Aaron Katz says the findings, "demonstrate that this specific mixture is able to stop abnormal cell growth and induce apoptosis (programmed cell death) in both hormone sensitive and hormone resistant prostate cancer cell lines at unusually low concentrations, which makes our findings especially significant... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 5, 2010 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Conclusions: In this population of healthy male volunteers, once-daily zibotentan 10 mg increased the AUC(0-infinity) of midazolam 1.2-fold; however, the treatment ratio was below the predefined limit for clinical significance. Zibotentan was well tolerated when given alone or in combination with midazolam. The results indicate that once-daily zibotentan 10 mg acted as a weak inhibitor of the CYP3A4 pathway. ClinicalTrials. gov identifier: NCT00709553.
PMID: 20678684 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - June 30, 2010 Category: Drugs & Pharmacology Authors: Tomkinson HK, Kemp JV, Wollseifen T, Morris T, Oliver SD Tags: Clin Ther Source Type: research
Clinical trials: Prostate Ca immunotherapy well tolerated
Sipuleucel-T (Provenge), an autologous cellular immunotherapy for metastatic, hormone-resistant
prostate cancer, demonstrated few adverse events compared with controls in analysis of randomized clinical trials
presented at the AUA annual meeting in San Francisco. (Source: Modern Medicine)
Source: Modern Medicine - June 19, 2010 Category: Journals (General) Source Type: news
Role of DNA methyltransferase 1 in hormone-resistant prostate cancer
In conclusion, altered DNMT1 expression
associated with activated STAT3 may be crucial in the transition of HR. Targeting DNMT1 could be a promising strategy for
the treatment of HR prostate, as evidenced by inhibited tumor growth and enhanced radiosensitivity. These findings provide
evidence for therapeutically targeting DNMT1 in HR prostate cancer.
Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00109-010-0640-3Authors
Miao-Fen Chen, Chang Gung Memorial Hospital Department of Radiation Oncology Taipei TaiwanWen-Cheng Chen, Chang Gung Memorial Hospital Department of Radiation Oncology Taipei Ta...
Source: Journal of Molecular Medicine - June 11, 2010 Category: Molecular Biology Tags: Journal of Molecular Medicine Source Type: research
AACR: Metformin Brakes Prostate Tumor Growth (CME/CE)
WASHINGTON (MedPage Today) -- The common anti-diabetes drug metformin appears to improve the ability of bicalutamide (Casodex), an androgen ablation drug, to slow proliferation in hormone-resistant prostate cancer cell lines, researchers reported here. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 25, 2010 Category: Hematology Source Type: news
AACR: Drug Combo Effective in Cancer Models (CME/CE)
WASHINGTON (MedPage Today) -- Researchers suggest that the combination of the thalidomide analogue, lenalidomide (Revlimid) and the taxane docetaxel (Taxotere) may be able to improve survival in cell and animal models of hormone-resistant metastatic prostate cancer. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 23, 2010 Category: Hematology Source Type: news
Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054)
Conclusions High-baseline HRQoL scores were maintained throughout treatment with zibotentan. The FACT-P instrument was selected to further
assess the impact of zibotentan on HRQoL in the Phase III clinical trial program.
Content Type Journal ArticleCategory Original PaperDOI 10.1007/s00432-010-0864-1Authors
Nancy Dawson, Georgetown University Lombardi Comprehensive Cancer Center Washington DC USAHeather Payne, University College Hospital London UKClare Battersby, AstraZeneca Pharmaceuticals Alderley Park Macclesfield, Cheshire SK10 4TF UKMaria Taboada, AstraZeneca Pharmaceuticals Alderley Park Maccle...
Source: Journal of Cancer Research and Clinical Oncology - April 13, 2010 Category: Cancer & Oncology Tags: Journal of Cancer Research and Clinical Oncology Source Type: research
Methoxychalcone induces cell-cycle arrest and apoptosis in human hormone-resistant prostate cancer cells through PI 3-kinase-independent inhibition of mTOR pathways
In this study, the anticancer mechanism of WJ9708011 (a methoxychalcone derivative) was delineated in human prostate cancer cells.Cell proliferation was examined by sulforhodamine B and clonogenic assays. Cell-cycle progression and mitochondrial membrane potential ([Delta][Psi]m) were detected by flow cytometric analysis. Expressions of protein and mRNA were detected by Western blot and RT-PCR technique, respectively. The protein synthesis was examined by [3H]leucine incorporation assay. The overexpression or knockdown techniques for specific target protein were also used in this study.WJ9708011 induced time- and concentra...
Source: The Prostate - March 29, 2010 Category: Urology & Nephrology Authors: Yu-Wei Sun, Wei-Jan Huang, Che-Jen Hsiao, Yi-Cheng Chen, Pin-Hsuan Lu, Jih-Hwa Guh Source Type: research
673 anti-tumor effect of dual pi3k/mtor inhibitor nvp-bez235 against docetaxel- and hormone-resistant human prostate cancer cell line
(Source: European Urology Supplements)
Source: European Urology Supplements - March 29, 2010 Category: Urology & Nephrology Authors: C.Y. Yoon, M.J. Park, S.W. Doo, H.Z. Park, D.S. Kim, W.K. Lee, S.H. Paick, S.J. Jeong, S.K. Hong, S.S. Byun, E.S. Lee, S.E. Lee Tags: Oral communications & discussed posters Source Type: research
Scientists Find Key to Hormone-Resistant Prostate Tumors
Title: Scientists Find Key to Hormone-Resistant Prostate TumorsCategory: Health NewsCreated: 3/10/2010 2:10:00 PMLast Editorial Review: 3/11/2010 (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - March 11, 2010 Category: Cancer & Oncology Source Type: news
Scientists Find Key to Hormone-Resistant Prostate Tumors
Title: Scientists Find Key to Hormone-Resistant Prostate TumorsCategory: Health NewsCreated: 3/10/2010 2:10:00 PMLast Editorial Review: 3/11/2010 (Source: MedicineNet Menopause General)
Source: MedicineNet Menopause General - March 11, 2010 Category: Primary Care Source Type: news
Scientists Find Key to Hormone-Resistant Prostate Tumors
Title: Scientists Find Key to Hormone-Resistant Prostate TumorsCategory: Health NewsCreated: 3/10/2010 2:10:00 PMLast Editorial Review: 3/11/2010 (Source: MedicineNet Mens Health General)
Source: MedicineNet Mens Health General - March 11, 2010 Category: Primary Care Source Type: news
Scientists Find Key to Hormone-Resistant Prostate Tumors
Discovery in mouse study may someday extend men's lives (Source: The Doctors Lounge - Endocrinology and Diabetes)
Source: The Doctors Lounge - Endocrinology and Diabetes - March 10, 2010 Category: Endocrinology Authors: webmaster at doctorslounge.com Tags: Endocrinology, Oncology, Reproductive Medicine, Research, Urology, News, Source Type: news
